Taiho Pharmaceutical

Shanghai Haihe Pharmaceutical Co., Ltd has entered into a licensing agreement with Taiho Pharmaceutical Co., Ltd, granting the Japanese company exclusive rights to develop, manufacture, and commercialize glumetinib, a MET-targeted tyrosine kinase inhibitor (TKI), in Japan and other Asian countries (excluding China) and Oceania. Haihe has already submitted a market…